Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

- PMLiVE

Powerful digital content management for the life sciences

Anthill Agency, a leading life sciences digital agency, has unveiled Anthill Activator™, which enables Veeva users to more efficiently manage their digital resources. Activator makes it easy to create and...

Anthill Agency

- PMLiVE

UK pharma Code of Practice to change with digital times

Changes proposed on the Code’s 60th anniversary

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

- PMLiVE

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

European approvals for Amgen and AstraZeneca

- PMLiVE

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even after discounts the medication exceeds the cost-effectiveness threshold

Pitch Perfect

What makes a perfect pitch? This week’s Thirsty Thursday – hosted by Louise Verrall, a managing director at Lucid Partners – was all about just that.Louise started her session with an involved...

Lucid Group Communications Limited

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

- PMLiVE

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare

- PMLiVE

Brexit medicine stockpiling could cost £2bn

Cost will be incurred whether a 'no deal' Brexit is avoided or not

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

BMS appoints new commercial leader, Davies joins Eisai and more

The latest industry movers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links